254 related articles for article (PubMed ID: 8420063)
1. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation.
Norman DJ; Kahana L; Stuart FP; Thistlethwaite JR; Shield CF; Monaco A; Dehlinger J; Wu SC; Van Horn A; Haverty TP
Transplantation; 1993 Jan; 55(1):44-50. PubMed ID: 8420063
[TBL] [Abstract][Full Text] [Related]
2. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
[TBL] [Abstract][Full Text] [Related]
3. Low-dose OKT3 for cadaveric renal transplantation.
Schweizer RT; Roper L; Hull D; Bartus SA
Transplant Proc; 1992 Dec; 24(6):2592-3. PubMed ID: 1465875
[No Abstract] [Full Text] [Related]
4. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation.
Shield CF; Jacobs RJ; Wyant S; Das A
Am J Kidney Dis; 1996 Jun; 27(6):855-64. PubMed ID: 8651251
[TBL] [Abstract][Full Text] [Related]
5. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
[TBL] [Abstract][Full Text] [Related]
6. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation.
Bock HA; Gallati H; Zürcher RM; Bachofen M; Mihatsch MJ; Landmann J; Thiel G
Transplantation; 1995 Mar; 59(6):830-40. PubMed ID: 7701577
[TBL] [Abstract][Full Text] [Related]
7. A randomized prospective trial of OKT3 induction in the current immunosuppression era.
Henry ML; Pelletier RP; Elkhammas EA; Bumgardner GL; Davies EA; Ferguson RM
Clin Transplant; 2001 Dec; 15(6):410-4. PubMed ID: 11737118
[TBL] [Abstract][Full Text] [Related]
8. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
[TBL] [Abstract][Full Text] [Related]
9. OKT3 prophylaxis in liver transplantation.
McDiarmid SV; Millis MJ; Terasaki PI; Ament ME; Busuttil RW
Dig Dis Sci; 1991 Oct; 36(10):1418-26. PubMed ID: 1833167
[TBL] [Abstract][Full Text] [Related]
10. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
[TBL] [Abstract][Full Text] [Related]
11. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
[TBL] [Abstract][Full Text] [Related]
12. Low-dose OKT3 induction therapy following renal transplantation: a controlled study.
Parlevliet KJ; ten Berge RJ; Raasveld MH; Surachno J; Wilmink JM; Schellekens PT
Nephrol Dial Transplant; 1994; 9(6):698-703. PubMed ID: 7970099
[TBL] [Abstract][Full Text] [Related]
13. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation.
Benfield MR; Tejani A; Harmon WE; McDonald R; Stablein DM; McIntosh M; Rose S;
Pediatr Transplant; 2005 Jun; 9(3):282-92. PubMed ID: 15910382
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients.
Schulak JA; Mayes JT; Moritz CE; Hricik DE
Transplantation; 1990 Feb; 49(2):327-32. PubMed ID: 2407003
[TBL] [Abstract][Full Text] [Related]
15. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
16. OKT3 for the treatment of steroid-resistant acute renal allograft rejection.
Jogose JT; Bailey RR; Lynn KL; Robson RA; Wells JE
Nephron; 1997; 77(3):298-303. PubMed ID: 9375823
[TBL] [Abstract][Full Text] [Related]
17. A prospective, double-blind, randomized study of high-versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation.
Norman DJ; Kimball JA; Bennett WM; Shihab F; Batiuk TD; Meyer MM; Barry JM
Transpl Int; 1994 Aug; 7(5):356-61. PubMed ID: 7993573
[TBL] [Abstract][Full Text] [Related]
18. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized comparison of cyclophosphamide and azathioprine for early rejection prophylaxis after cardiac transplantation. Decreased sensitization to OKT3.
Taylor DO; Bristow MR; O'Connell JB; Ensley RD; Olsen SL; Hammond EH; Wagoner LE; Renlund DG
Transplantation; 1994 Sep; 58(6):645-9. PubMed ID: 7940682
[TBL] [Abstract][Full Text] [Related]
20. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function.
Benvenisty AI; Cohen D; Stegall MD; Hardy MA
Transplantation; 1990 Feb; 49(2):321-7. PubMed ID: 2137654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
